Related Experiment Video
Updated: Aug 14, 2026
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Radiotherapy Strategies for WHO Grade 1 Meningioma: A Systematic Review and Meta-Analysis Comparing Proton Therapy,
Hazuki Nitta1,2, Masashi Mizumoto1, Kazushi Maruo3
1Department of Radiation Oncology, University of Tsukuba, Tsukuba 305-8576, Ibaraki, Japan.
Cancers
|August 13, 2026
Summary
Different radiotherapy options provide similar excellent local control for WHO Grade 1 meningioma. Conventionally fractionated proton therapy and photon radiotherapy showed favorable outcomes, even with larger tumors compared to stereotactic methods.
Area of Science:
- Radiation Oncology
- Neurosurgery
- Medical Physics
Background:
- Optimal radiotherapy for World Health Organization (WHO) Grade 1 meningioma is unclear.
- Proton therapy offers potential dosimetric benefits, but comparative data are limited.
- Systematic review and meta-analysis needed for contemporary radiotherapy modalities.
Purpose of the Study:
- Compare local control (LC) outcomes for WHO Grade 1 meningioma.
- Evaluate conventionally fractionated proton therapy (CF-PT), conventionally fractionated photon radiotherapy (CF-Photon RT), Linac-based stereotactic radiosurgery/radiotherapy (Linac-based SRS/SRT), and Gamma Knife radiosurgery (GKRS).
Main Methods:
- Systematic literature search of PubMed (2000-2024).
- Random-effects meta-analyses to estimate pooled 1- to 5-year LC rates.
- Meta-regression analysis with modality, age, sex, and GTV as covariates.
Main Results:
- 24 studies, 4673 patients included.
- All modalities demonstrated excellent LC: 5-year LC rates ranged from 89.8% (GKRS) to 95.9% (CF-PT).
- No significant association found between modality or GTV and LC.
Conclusions:
- Major radiotherapy modalities achieve comparable and excellent local control for WHO Grade 1 meningioma.
- CF-PT and CF-Photon RT showed favorable LC with larger tumors than stereotactic approaches.
- Further research required for long-term control and toxicity to guide optimal treatment.
